Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Employees - 61000,
CEO - Mr. Rainer M. Blair,
Sector - Healthcare,
Country - US,
Market Cap - 166.82B
Altman ZScore(max is 10): 4.62, Piotroski Score(max is 10): 7, Working Capital: $2721000000, Total Assets: $80615000000, Retained Earnings: $43296000000, EBIT: 4907000000, Total Liabilities: $29310000000, Revenue: $20030000000
AryaFin Target Price - $225.7 - Current Price $228.55 - Analyst Target Price $288.25
Ticker | DHR |
Index | S&P 500 |
Curent Price | 228.55 |
Change | 1.06% |
Market Cap | 166.82B |
Average Volume | 2.87M |
Income | 3.89B |
Sales | 23.74B |
Book Value/Share | 71.03 |
Cash/Share | 3.60 |
Dividend Est | 1.10 (0.48%) |
Dividend TTM | 1.05 (0.46%) |
Dividend Ex-Date | Dec 27, 2024 |
Employees | 63000 |
Moving Avg 20days | -2.55% |
Moving Avg 50days | -6.22% |
Moving Avg 200days | -10.34% |
Shares Outstanding | 722.20M |
Earnings Date | Oct 22 BMO |
Inst. Ownership | 80.59% |
Price/Earnings | 43.59 |
Forwad P/E | 27.42 |
PE Growth | 7.42 |
Price/Sales | 7.03 |
Price/Book | 3.22 |
Price/Cash | 63.50 |
Price/FCF | 33.30 |
Quick Ratio | 1.01 |
Current Ratio | 1.37 |
Debt/Equity | 0.37 |
Return on Assets | 4.67% |
Return on Equity | 7.59% |
Return on Investment | 5.76% |
Gross Margin | 59.37% |
Ops Margin | 20.44% |
Profit Margin | 16.39% |
RSI | 37.57 |
BETA(β) | 0.84 |
From 52week Low | 2.71% |
From 52week High | -18.87% |
EPS | 5.24 |
EPS next Year | 8.34 |
EPS next Qtr | 2.15 |
EPS this Year | -1.15% |
EPS next 5 Year | 5.87% |
EPS past 5 Year | 11.31% |
Sales past 5 Year | 8.35% |
EPS Y/Y | -34.04% |
Sales Y/Y | -19.70% |
EPS Q/Q | -25.91% |
Sales Q/Q | -15.64% |
Sales Surprise | 3.78% |
EPS Surprise | 9.02% |
ATR(14) | 4.72 |
Perf Week | -2.70% |
Perf Month | -1.95% |
Perf Quarter | -16.33% |
Perf Year | 0.77% |
Perf YTD | -1.21% |
Target Price | 288.25 |
AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer